Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is too much neurohormonal blockade harmful?

Inder S Anand1

  • 1VA Medical Center, One Veterans Drive, 111-C, Minneapolis, MN 55417, USA. anand001@umn.edu

Current Cardiology Reports
|April 13, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Performance of the HFpEF-ABA, H<sub>2</sub>FPEF, and HFA-PEFF Algorithms in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials.

Journal of cardiac failure·2026
Same author

Heart rate and atrial fibrillation/flutter in HFmrEF/HFpEF: a participant-level analysis across five randomized clinical trials.

European journal of heart failure·2026
Same author

Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.

Journal of the American College of Cardiology·2025
Same author

Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials.

Journal of the American College of Cardiology·2025
Same author

Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF.

European heart journal. Cardiovascular pharmacotherapy·2025
Same author

Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary Trials.

JACC. Heart failure·2025

Heart failure treatments targeting the sympathetic and renin-angiotensin-aldosterone systems improve survival. However, blocking other neurohormones offers limited benefit, suggesting a ceiling effect in heart failure therapy.

Area of Science:

  • Cardiology
  • Neuroendocrinology
  • Pharmacology

Background:

  • Neurohormones and cytokines are activated in heart failure, influencing disease progression.
  • Established therapies targeting the sympathetic nervous system and renin-angiotensin-aldosterone system significantly improve heart failure patient survival.

Purpose of the Study:

  • To review studies on neurohormonal blockade in heart failure.
  • To analyze the reasons behind the limited efficacy of inhibiting certain neurohormones and cytokines.

Main Methods:

  • Review of existing clinical studies and research on heart failure pharmacotherapy.
  • Analysis of data regarding the effects of various neurohormonal blockade strategies.

Main Results:

Related Experiment Videos

  • Inhibition of the sympathetic and renin-angiotensin-aldosterone systems with specific drugs (e.g., beta-blockers, ACE inhibitors) is effective.
  • Targeting other neurohormones and cytokines has not yielded expected benefits and can be detrimental.

    • Conclusions:

    • There may be a limit to the benefits of further neurohormonal blockade in heart failure.
    • Understanding these limitations is crucial for developing future heart failure treatment strategies.